hhvb glp 1 drops reviews Beyond Ozempic: The GLP-1 boom GLP-1 Medications for Type 2

SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]

[DOI] [PubMed] [Google Scholar] 64.Koska J, et al

Tirzepatide - a dual GIP/GLP-1 receptor agonist that acts on two hormone pathways

These developments will have implications for numerous stakeholders within the industry

I think this is an overblown concern

To view or add a comment, sign in More from this author Explore related topics Explore content categories